MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study


Journal article


Christopher D. Barrett, H. Moore, Ernest E. Moore, D. Benjamin Christie, S. Orfanos, L. Anez-Bustillos, Rashi Jhunjhunwala, S. Hussain, S. Shaefi, Janice Wang, N. Hajizadeh, Elias N. Baedorf-Kassis, Ammar Al‐Shammaa, Krystal Capers, V. Banner-Goodspeed, F. Wright, T. Bull, Peter K. Moore, Hannah M. Nemec, John Thomas Buchanan, Cory Nonnemacher, Natalie Rajcooar, Ramona Ramdeo, M. Yacoub, A. Guevara, Aileen Espinal, L. Hattar, A. Moraco, R. McIntyre, D. Talmor, A. Sauaia, M. Yaffe
Research and Practice in Thrombosis and Haemostasis, 2022

Semantic Scholar DOI PubMedCentral PubMed
Cite

Cite

APA   Click to copy
Barrett, C. D., Moore, H., Moore, E. E., Christie, D. B., Orfanos, S., Anez-Bustillos, L., … Yaffe, M. (2022). MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study. Research and Practice in Thrombosis and Haemostasis.


Chicago/Turabian   Click to copy
Barrett, Christopher D., H. Moore, Ernest E. Moore, D. Benjamin Christie, S. Orfanos, L. Anez-Bustillos, Rashi Jhunjhunwala, et al. “MUlticenter STudy of Tissue Plasminogen Activator (Alteplase) Use in COVID‐19 Severe Respiratory Failure (MUST COVID): A Retrospective Cohort Study.” Research and Practice in Thrombosis and Haemostasis (2022).


MLA   Click to copy
Barrett, Christopher D., et al. “MUlticenter STudy of Tissue Plasminogen Activator (Alteplase) Use in COVID‐19 Severe Respiratory Failure (MUST COVID): A Retrospective Cohort Study.” Research and Practice in Thrombosis and Haemostasis, 2022.


BibTeX   Click to copy

@article{christopher2022a,
  title = {MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study},
  year = {2022},
  journal = {Research and Practice in Thrombosis and Haemostasis},
  author = {Barrett, Christopher D. and Moore, H. and Moore, Ernest E. and Christie, D. Benjamin and Orfanos, S. and Anez-Bustillos, L. and Jhunjhunwala, Rashi and Hussain, S. and Shaefi, S. and Wang, Janice and Hajizadeh, N. and Baedorf-Kassis, Elias N. and Al‐Shammaa, Ammar and Capers, Krystal and Banner-Goodspeed, V. and Wright, F. and Bull, T. and Moore, Peter K. and Nemec, Hannah M. and Buchanan, John Thomas and Nonnemacher, Cory and Rajcooar, Natalie and Ramdeo, Ramona and Yacoub, M. and Guevara, A. and Espinal, Aileen and Hattar, L. and Moraco, A. and McIntyre, R. and Talmor, D. and Sauaia, A. and Yaffe, M.}
}

Abstract

Few therapies exist to treat severe COVID‐19 respiratory failure once it develops. Given known diffuse pulmonary microthrombi on autopsy studies of COVID‐19 patients, we hypothesized that tissue plasminogen activator (tPA) may improve pulmonary function in COVID‐19 respiratory failure.